Shares of Orexigen Therapeutics Inc. dropped in the extended session Thursday following a report alleging data for the biotech's obesity treatment might be unreliable. Shares of Orexigen fell 14% to $6.89 on heavy volume. Late Thursday, Forbes ran a report quoting John Jenkins, director of the Office of New Drugs at the Food and Drug Administration, saying that data showing Orexigen's Contrave lowered the risk of heart attack was "unreliable."
Copyright © 2015 MarketWatch, Inc.
Continue Reading Below